Compare FNKO & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNKO | SGMT |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 192.7M | 204.2M |
| IPO Year | 2017 | 2023 |
| Metric | FNKO | SGMT |
|---|---|---|
| Price | $4.06 | $5.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $5.50 | ★ $27.00 |
| AVG Volume (30 Days) | ★ 1.1M | 845.8K |
| Earning Date | 03-05-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $928,842,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.54 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.22 | $1.73 |
| 52 Week High | $14.28 | $11.41 |
| Indicator | FNKO | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 56.64 | 40.85 |
| Support Level | $3.89 | $5.02 |
| Resistance Level | $4.31 | $7.20 |
| Average True Range (ATR) | 0.30 | 0.49 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 58.08 | 19.91 |
Funko Inc is an USA based pop culture consumer products company. It creates whimsical, fun, and different products that enable the customer to express their affinity for their favorite through the movie, TV show, video game, musician, or sports team. The company's current products are principally figures, fashion accessories, apparel, plush products, accessories, homewares, and NFTs. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites. The company generates the majority of its revenue from the core collectibles products.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.